CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors

Yan Chen; Zhi Yang; Xueyun Gao; Hua Zhu

doi:10.1016/j.jpha.2023.08.007

Volume 13 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(9): 955-957

Yan Chen, Zhi Yang, Xueyun Gao, Hua Zhu. CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 955-957. doi: 10.1016/j.jpha.2023.08.007

Citation:

Yan Chen, Zhi Yang, Xueyun Gao, Hua Zhu. CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 955-957. doi: 10.1016/j.jpha.2023.08.007

Citation:

PDF( 369 KB)

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors

doi: 10.1016/j.jpha.2023.08.007

Yan Chen^1,2,
Zhi Yang³,
Xueyun Gao^{4
,
,},
Hua Zhu^{5,6
,
,}

1. The Ministry of Education Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China;
2. Faculty of Environment and Life, Beijing University of Technology, Beijing, 100124, China;
3. The Ministry of Education Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China;
4. Faculty of Environment and Life, Beijing University of Technology, Beijing, 100124, China;
5. The Ministry of Education Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China;
6. Faculty of Environment and Life, Beijing University of Technology, Beijing, 100124, China

Publish Date: Aug. 18, 2023

Abstract

FullText(HTML)

References(5)

References

S. Tabaries, P.M. Siegel, The role of claudins in cancer metastasis, Oncogene 36 (2017) 1176-1190.

K. Shitara, F. Lordick, Y.-J. Bang, et al., Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial, Lancet. 401 (2023) 1655-1668.

C. Zhao, Z. Rong, J. Ding, et al., Targeting claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery, Mol. Pharm. 19 (2022) 3530-3541.

S. Wang, C. Qi, J. Ding, et al., First-in-human CLDN18.2 functional diagnostic PET imaging of digestive system neoplasms enables whole-body target mapping and lesion detection, Eur. J. Nucl. Med. Mol Imaging 50 (2023) 2802-2817.

Y. Chen, X. Hou, D. Li, et al., Development of a CLDN18.2-targeting immuno-pet probe for non-invasive imaging in gastrointestinal tumors, J. Pharm. Anal. 13 (2023) 367-375.

Relative Articles

Supplements(0)

Cited By

Proportional views